# Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

> **NCT03972488** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Advanced Accelerator Applications** · enrollment: 226 (actual)

## Conditions studied

- Gastro-enteropancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Lutathera
- **DRUG:** 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)
- **DRUG:** 2.5% Lys-Arg sterile amino acid solution
- **DRUG:** High dose 60 mg octreotide long-acting repeatable

## Key facts

- **NCT ID:** NCT03972488
- **Lead sponsor:** Advanced Accelerator Applications
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-08
- **Primary completion:** 2023-07-20
- **Final completion:** 2027-10-29
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03972488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03972488, "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03972488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*